Alnylam Pharmaceuticals, Inc.
ALNY
$438.93
$3.830.88%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -15.31% | 31.38% | 24.92% | -560.61% | 74.39% |
| Total Depreciation and Amortization | -3.20% | 170.11% | -175.99% | 80.22% | 10.99% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 10.00% | 69.10% | -14.00% | -40.69% | 107.15% |
| Change in Net Operating Assets | 123.07% | -192.47% | -341.50% | 180.12% | 64.64% |
| Cash from Operations | 229.93% | -24.99% | -316.58% | -64.80% | 252.31% |
| Capital Expenditure | -59.34% | 1.36% | -116.94% | 47.72% | 38.19% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -203.54% | 380.12% | -68.15% | -162.10% | 176.78% |
| Cash from Investing | -224.27% | 315.02% | -74.91% | -189.13% | 150.19% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 64.53% | 36.07% | -66.42% | -18.63% | 413.47% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -420.07% | 0.00% | 0.00% | -311.93% | -142.01% |
| Cash from Financing | 21.94% | 42.22% | -69.83% | -21.86% | 354.83% |
| Foreign Exchange rate Adjustments | 95.66% | 181.40% | -214.43% | 583.75% | 68.61% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 74.66% | 140.04% | -201.94% | -54.17% | 320.09% |